ASP Isotopes (ASPI) moved into focus after its Tetra4 subsidiary secured a five-year take-or-pay helium supply contract from the Virginia Gas Project in South Africa at initial prices above $600 per thousand cubic feet.

At a latest share price of $7.08, ASP Isotopes has a 30-day share price return of 27.57% and a 90-day share price return of 40.48%. This points to building momentum despite a 1-year total shareholder return that is down 7.93% and a very large 3-year total shareholder return that suggests early investors have already seen substantial swings in value.

If this kind of contract-driven story interests you, it can be useful to see what else is moving in related areas and uncover 29 best rare earth metal stocks

With ASP Isotopes now tied into a premium helium contract and the stock up sharply over the past quarter yet still down over the past year, is the current price a fresh opportunity, or is the market already assuming years of future growth?

Preferred Price-to-Sales of 33.1x: Is it justified?

ASP Isotopes trades on a P/S ratio of 33.1x, and at a last close of $7.08, that points to a rich valuation compared with both peers and the wider US Chemicals industry.

The P/S ratio compares the company’s market value with its revenue and is often used where profits are not yet in place. For ASP Isotopes, this matters because the company reported revenue of $26.93 million while remaining loss making, so the market is effectively pricing the stock on sales potential rather than current earnings.

On that basis, ASP Isotopes looks expensive relative to several benchmarks. The stock’s 33.1x P/S is far above the estimated fair P/S ratio of 6.6x, a level that represents where the multiple could settle if expectations cool or revenue expands without the share price keeping pace. It also stands well above the US Chemicals industry average P/S of 1.1x and the peer group average of 1.9x. This suggests investors are paying a sizeable premium for its growth profile and helium contract story.

Result: Price-to-Sales of 33.1x (OVERVALUED)

However, ASP Isotopes still faces clear risks, including continued losses of $193.109 million and heavy reliance on a premium helium contract to support its valuation.

Next Steps

Given the mixed sentiment around ASP Isotopes, with clear risks and some potential rewards, it makes sense to review the full picture for yourself. You can start with the 2 key rewards and 3 important warning signs.

Looking for more investment ideas beyond ASP Isotopes?

If ASP Isotopes has sharpened your appetite for opportunity, do not stop here. Broaden your watchlist and keep fresh ideas coming through a few focused screens.

• Target potential bargains by scanning for companies trading below what their fundamentals might suggest using the 44 high quality undervalued stocks.
• Strengthen your income stream by focusing on businesses with higher yields and resilient payouts through the 7 dividend fortresses.
• Dial down portfolio risk by concentrating on companies that score well on resilience and stability with the 67 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.